Cell-adhesion molecules and their soluble forms: Promising predictors of “tumor progression” and relapse in leukemia

• Published in: Tumor Biology Vol. 40; no. 11; p. 1010428318811525
• Main Authors: Fonseca, Ieda Cristina Cunha Ferreira e, da Luz, Felipe Andrés Cordero, Uehara, Isadora Akemi, Silva, Marcelo José Barbosa
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.11.2018; Sage Publications Ltd; IOS Press
• Subjects: Cadherins; Cancer; Carcinoma; CD44 antigen; Cell adhesion; Cell adhesion & migration; Cell adhesion molecules; Cell Adhesion Molecules - metabolism; Disease Progression; E-cadherin; Epithelial cells; Hematology; Humans; Leukemia; Leukemia - metabolism; Leukemia - pathology; Metastases; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Prognosis; Proteins; Serum levels; Stem cells; Surface markers; leukemia; tumor progression; Cell-adhesion molecules; relapse; soluble forms
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1177/1010428318811525

Some surface markers are used to discriminate certain leukemic subpopulations that retain a greater oncogenic potential than others, and, for this reason, they were termed as leukemic stem cells, similar to the concept of cancer stem cells in carcinoma. Among these surface markers are proteins involved in cell–cell adhesion or cell–matrix adhesion, and they may play a role in the relapse of leukemia, similar to metastasis in carcinomas. The most important are epithelial cadherin, neural cadherin, epithelial cell-adhesion molecule, and CD44, which can be cleaved and released, and their soluble forms were found increased in serum levels of cancer patients, being implicated, in some cases, with progression, metastases, and relapse. In this review, we highlighted the role of these four adhesion molecules in carcinomas and hematological malignancies, mainly leukemia, and discuss if the serum levels of soluble forms can be correlated with the surface protein status on the leukemic cells. Accession of the soluble forms looks attractive, but their use as markers in cancer must be studied in association with other parameters, as there are significant changes in levels in other pathological conditions besides cancer. Studies correlating the levels of the forms with the status of the membrane-bound proteins in leukemic (stem) cells and correlating those parameters with relapse in leukemia may afford important knowledge and applicability of those serum markers in clinical practice. For instance, the expression of the membrane-bound forms of these adhesion proteins may have promising clinical use in leukemia and other hematological malignancies.